Ontology highlight
ABSTRACT: Background
Clinical sequencing using a panel of genes has recently been applied worldwide for patients with refractory solid tumors, but the significance of clinical sequencing using gene panel testing remains uncertain. Here we sought to clarify the feasibility and utility of clinical sequencing in the treatment of refractory tumors at our hospital.Methods
A total of 39 patients with advanced solid tumors treated at our hospital between 2018 and 2020 were enrolled in the clinical sequencing. Among them, we identified 36 patients whose tissue samples were of suitable quality for clinical sequencing, and we analyzed the genomic profiles of these tumors.Results
Pathogenic alterations were detected in 28 (78%) of the 36 patients. The most common mutation was TP53 (55%)
SUBMITTER: Nishimura S
PROVIDER: S-EPMC7909652 | biostudies-literature | 2021
REPOSITORIES: biostudies-literature